tera.ai

Knowledge Graph

Graph explorer

Search resolved entities, walk their edges, and read the sentence behind every one.

Entities25 of 207,987

All entities

Entity

ACR-2316

product1 mentionslast seen Nov 6, 2026

First-in-class, potent, selective WEE1/PKMYT1 inhibitor in Phase 1/2 development.

Relationships 1

ACR-2316

Relationship

Acrivon Therapeutics, Inc.developsACR-2316

96% confidence1 supporting mentions

Either name opens that entity’s relationships.

Sources 1